Global Myocardial Infarction Drugs Market 2016-2020

2016-03-08
Price :
Published : Mar-2016
No. of Pages : 75

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

The analysts forecast global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report

This report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

The report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi

Other prominent vendors

  • advanceCOR
  • Armaron Bio
  • Athersys
  • BioVascular
  • BMS
  • Caladrius
  • Capricor
  • CSL Behring
  • GNT Pharma
  • GSK
  • Ischemix
  • Mesoblast
  • NeuroVive
  • Osiris Therapeutics
  • PledPharma
  • RegeneRx
  • Teva Pharmaceuticals
  • TiGenix
  • US Stem Cell
  • Ventrix

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Growing awareness of disease
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
Filed in: Pharmaceutical
Publisher : Technavio
More Reports
Title Price Buy Now

ForeSights: Salt Therapy – An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution

ForeSights: Salt Therapy - An old-fashioned, non-invasive treatment enjoying a renaissance as a new health and wellness solution Summary Salt therapy is a non-invasive treatment that uses aerated salt or a salt bath to deliver health and wellness benefits. It comes in two forms: dry salt therapy (halotherapy) and wet salt therapy (flotation therapy). Both forms of salt therapy are claimed to promote relaxation and rejuvenation. Salt therapy is an old-fashioned, drug-free treatment leveraging the claimed natural antibacterial and anti-inflammatory properties of salt that capitalizes on growing interest in complementary and alternative medicine. Scope - Dry salt therapy (halotherapy) takes mineral-rich salt and grinds it into a fine powder that is dispensed into the air to cre......
$495

EpiCast Report: Osteoarthritis – Epidemiology Forecast to 2026

EpiCast Report: Osteoarthritis - Epidemiology Forecast to 2026 Summary Osteoarthritis (OA) is a gradually progressive joint disease that is typically seen in middle-aged to elderly people. According to the American College of Rheumatology (ACR), OA is the most common cause of disability in the elderly. The most commonly affected joints are the knee, hip, hand, and spine. It is characterized by breakdown of the cartilage, bony changes of the joints, deterioration of tendons and ligaments, and various degrees of inflammation of the joint lining. To forecast the total prevalent cases (radiographic), total prevalent cases (symptomatic), and diagnosed prevalent cases (symptomatic) of hand OA, knee OA, and hip OA in the 7MM, GlobalData epidemiologists selected nationally representative,......
$3995

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017

Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helicobacter pylori Infections Global Clinical Trials Review, H2, 2017" provides an overview of Helicobacter pylori Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Helicobacter pylori Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's......
$2500

Helminthiasis Global Clinical Trials Review, H2, 2017

Helminthiasis Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthiasis Global Clinical Trials Review, H2, 2017" provides an overview of Helminthiasis clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthiasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clin......
$2500

Helminthic Infestations Global Clinical Trials Review, H2, 2017

Helminthic Infestations Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Helminthic Infestations Global Clinical Trials Review, H2, 2017" provides an overview of Helminthic Infestations clinical trials scenario. This report provides top line data relating to the clinical trials on Helminthic Infestations. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Phar......
$2500

Hemangiomas Global Clinical Trials Review, H2, 2017

Hemangiomas Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hemangiomas Global Clinical Trials Review, H2, 2017" provides an overview of Hemangiomas clinical trials scenario. This report provides top line data relating to the clinical trials on Hemangiomas. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical tri......
$2500

Hematological Tumor Global Clinical Trials Review, H2, 2017

Hematological Tumor Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematological Tumor Global Clinical Trials Review, H2, 2017" provides an overview of Hematological Tumor clinical trials scenario. This report provides top line data relating to the clinical trials on Hematological Tumor. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinic......
$2500

Hematoma Global Clinical Trials Review, H2, 2017

Hematoma Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematoma Global Clinical Trials Review, H2, 2017" provides an overview of Hematoma clinical trials scenario. This report provides top line data relating to the clinical trials on Hematoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are coll......
$2500

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017

Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017 Summary GlobalData's clinical trial report, "Hematopoietic Stem Cell Transplantation Global Clinical Trials Review, H2, 2017" provides an overview of Hematopoietic Stem Cell Transplantation clinical trials scenario. This report provides top line data relating to the clinical trials on Hematopoietic Stem Cell Transplantation. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Repo......
$2500

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provide......
$1000